Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14530522rdf:typepubmed:Citationlld:pubmed
pubmed-article:14530522lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0175677lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0181078lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:14530522lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:14530522pubmed:issue9lld:pubmed
pubmed-article:14530522pubmed:dateCreated2003-10-7lld:pubmed
pubmed-article:14530522pubmed:abstractTextSmall animal models with the capacity to support engraftment of a functional human immune system are needed to facilitate studies of human alloimmunity. In the present investigation, non-obese diabetic (NOD) severe combined immunodeficient (scid) beta2-microglobulin-null (B2mnull) mice engrafted with human peripheral blood lymphocytes (hu-PBL-NOD-scid B2mnull mice) were used as in vivo models for studying human skin allograft rejection. Hu-PBL-NOD-scid B2mnull mice were established by injection of human spleen cells or PBLs and transplanted with full-thickness allogeneic human skin. Human cell engraftment was enhanced by injection of anti-mouse CD122 antibody. The respective contributions of human CD4+ and CD8+ cells in allograft rejection were determined using depleting antibodies. Human skin grafts on unmanipulated NOD-scid B2mnull mice uniformly survived but on chimeric hu-PBL-NOD-scid B2mnull mice exhibited severe immune-mediated injury that often progressed to complete rejection. The alloaggressive hu-PBLs did not require prior in vitro sensitization to elicit targeted effector cell activity. Extensive mononuclear cell infiltration directed towards human-origin endothelium was associated with thrombosis and fibrin necrosis. No evidence of graft-versus-host disease was detected. Either CD4+ or CD8+ T cells may mediate injury and alloimmune rejection of human skin grafts on hu-PBL-NOD-scid B2mnull mice. It is proposed that Hu-PBL-NOD-scid B2mnull mice engrafted with human skin will provide a useful model for analysis of interventions designed to modulate human allograft rejection.lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:languageenglld:pubmed
pubmed-article:14530522pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:citationSubsetIMlld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14530522pubmed:statusMEDLINElld:pubmed
pubmed-article:14530522pubmed:monthOctlld:pubmed
pubmed-article:14530522pubmed:issn1535-3702lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:TurgeonNicole...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:RossiniAldo...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:LyonsBonnie...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:ShultzLeonard...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:GreinerDale...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:MordesJohn...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:BanuelosScott...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:AppelMichael...lld:pubmed
pubmed-article:14530522pubmed:authorpubmed-author:IwakoshiNealNlld:pubmed
pubmed-article:14530522pubmed:issnTypePrintlld:pubmed
pubmed-article:14530522pubmed:volume228lld:pubmed
pubmed-article:14530522pubmed:ownerNLMlld:pubmed
pubmed-article:14530522pubmed:authorsCompleteYlld:pubmed
pubmed-article:14530522pubmed:pagination1096-104lld:pubmed
pubmed-article:14530522pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:meshHeadingpubmed-meshheading:14530522...lld:pubmed
pubmed-article:14530522pubmed:year2003lld:pubmed
pubmed-article:14530522pubmed:articleTitleAlloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice.lld:pubmed
pubmed-article:14530522pubmed:affiliationUniversity of Massachusetts Medical School, Worcester, Massachussetts 01605, USA.lld:pubmed
pubmed-article:14530522pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14530522pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14530522pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14530522lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14530522lld:pubmed